MARKET

RPHM

RPHM

Reneo Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.718
+0.138
+5.35%
Opening 10:12 08/11 EDT
OPEN
2.570
PREV CLOSE
2.580
HIGH
2.780
LOW
2.570
VOLUME
13.62K
TURNOVER
32.00K
52 WEEK HIGH
11.40
52 WEEK LOW
1.920
MARKET CAP
66.48M
P/E (TTM)
-1.4161
1D
5D
1M
3M
1Y
5Y
BRIEF-Reneo Pharmaceuticals Posts Q2 Loss Per Share $0.50
BRIEF-Reneo Pharmaceuticals Posts Q2 Loss Per Share $0.50
Reuters · 2d ago
Reneo Pharmaceuticals GAAP EPS of -$0.50 beats by $0.08
Reneo Pharmaceuticals press release (<span class="ticker-hover-wrapper...
Seekingalpha · 2d ago
Insiders who bought in the last 12 months lose an additional US$83k as Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) drops to US$57m
Insiders who bought US$120k worth of Reneo Pharmaceuticals, Inc.'s ( NASDAQ:RPHM ) stock at an average buy price of...
Simply Wall St. · 08/04 13:10
BRIEF-Reneo Pharmaceuticals Appoints Roshawn Blunt To Its Board Of Directors
BRIEF-Reneo Pharmaceuticals Appoints Roshawn Blunt To Its Board Of Directors
Reuters · 08/02 11:51
Reneo Pharmaceuticals Says Metabolic Disorder Program To Enter Next Stage Of Development
Reneo Pharmaceuticals Inc (NASDAQ: RPHM) has reported results from the REN001 long-chain fatty acid oxidation disorders (LC-FAOD) study and provided additional development updates. In the LC-FAOD Phase 1b study, REN001 was safe and well tolerated. The most...
Benzinga · 07/26 13:52
Reneo Pharmaceuticals Reports Results From REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study And Provides Additional Development Updates
LC-FAOD program to move forward into the next stage of clinical development Enrollment of pivotal STRIDE study in primary mitochondrial myopathies (PMM) patients with mitochondrial DNA (mtDNA) defects on track to be
Benzinga · 07/26 11:37
Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates
LC-FAOD program to move forward into the next stage of clinical developmentEnrollment of pivotal STRIDE study in primary mitochondrial myopathies (PMM) patients with mitochondrial DNA (mtDNA) defects on track to be completed year-end 2022Alignment with Eur...
GlobeNewswire · 07/26 11:30
Reneo Pharmaceuticals Reports Positive Results from REN001 Study
Reneo Pharmaceuticals Reports Positive Results from REN001 Study
MT Newswires · 07/26 09:09
More
No Data
Learn about the latest financial forecast of RPHM. Analyze the recent business situations of Reneo Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

80.00%Strong Buy
20.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RPHM stock price target is 26.33 with a high estimate of 42.00 and a low estimate of 15.00.
High42.00
Average26.33
Low15.00
Current 2.718
EPS
Actual
Estimate
-0.46-0.35-0.23-0.12
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 42
Institutional Holdings: 17.29M
% Owned: 70.71%
Shares Outstanding: 24.46M
TypeInstitutionsShares
Increased
8
36.84K
New
5
49.88K
Decreased
13
140.17K
Sold Out
3
66.83K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.83%
Pharmaceuticals & Medical Research
-0.23%
Key Executives
Chairman/Executive Director
Michael Grey
President/Chief Executive Officer/Director
Gregory Flesher
Co-Founder/Director
Niall O'Donnell
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance/Vice President - Administration
Jennifer Lam
Chief Operating Officer
Michael Cruse
Other
Alejandro Dorenbaum
Other
Ashley Hall
Director
Roshawn Blunt
Independent Director
Eric Dube
Independent Director
Paul Hoelscher
Independent Director
Edward Mathers
Independent Director
Bali Muralidhar
Independent Director
Stacey Seltzer
No Data
No Data
About RPHM
Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the developing therapies for patients with rare genetic mitochondrial diseases. The Company is engaged in developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the source of energy for cellular processes. REN001 is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist that has been shown to transcription of genes involved in mitochondrial function and fatty acid oxidation (FAO). The Company is developing REN001 in the three rare genetic diseases that present with myopathy and have unmet medical need: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disease type V (McArdle disease). The Company has completed Phase I b clinical trial in patients with PMM to REN001. It is conducting open-label Phase I b clinical trials of REN001 with LC-FAOD and with McArdle disease.

Webull offers kinds of Reneo Pharmaceuticals Inc stock information, including NASDAQ:RPHM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RPHM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RPHM stock methods without spending real money on the virtual paper trading platform.